NCT06338553

GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

Name: Clinical Trial NCT06338553
Creator: Vanderbilt University Medical Center
Keywords: Type 1 Diabetes, Placebo, Phase 1, drug, clinical trial, United States of America

Optimizing Stage 2 T1DM Management: Assessing the Impact of GLP-1Ra on Metabolic Outcomes in Patients Receiving Teplizumab

Vanderbilt University Medical Center·Phase 1·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Type 1 Diabetes
Drug/Device/Intervention: Placebo
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Vanderbilt University Medical Center
Location: Nashville, United States of America

Timeline & enrollment

Phase: Phase 1
Start date: Jun 01, 2024
End date: Mar 01, 2027
Enrollment: 24 participants

Primary outcome

Investigate the impact of GLP-1Ra on postprandial glycemia in a pilot study,Study the impact of GLP-1Ra on the disposition index (DI) in a pilot study,Determine the impact of GLP-1Ra on endothelial function in a pilot study

Summary

The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment. This study involves giving participants a liquid meal under three different conditions and observing how their bodies respond, focusing on blood sugar levels, insulin effectiveness, and blood vessel function. The first meal test is pre-teplizumab, followed by two post-treatment tests, one with the GLP-1Ra drug and the other with a placebo. Each test involves blood draws before and during the meal test, GLP-1Ra or placebo administration, and an ultrasound to measure blood vessel function. The goal is to see if GLP-1Ra can help manage blood sugar levels and improve cardiovascular health in this population.

ICD-10 classifications

Type 1 diabetes mellitusType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus with multiple complications

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06338553
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06338553 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vanderbilt University Medical Center and is currently Recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.